JP2024508672A5 - - Google Patents

Info

Publication number
JP2024508672A5
JP2024508672A5 JP2023547592A JP2023547592A JP2024508672A5 JP 2024508672 A5 JP2024508672 A5 JP 2024508672A5 JP 2023547592 A JP2023547592 A JP 2023547592A JP 2023547592 A JP2023547592 A JP 2023547592A JP 2024508672 A5 JP2024508672 A5 JP 2024508672A5
Authority
JP
Japan
Prior art keywords
variable region
chain variable
seq
nos
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015711 external-priority patent/WO2022170280A2/en
Publication of JP2024508672A publication Critical patent/JP2024508672A/ja
Publication of JP2024508672A5 publication Critical patent/JP2024508672A5/ja
Pending legal-status Critical Current

Links

JP2023547592A 2021-02-08 2022-02-08 新規抗ｃｄ２４抗体 Pending JP2024508672A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021076075 2021-02-08
CNPCT/CN2021/076075 2021-02-08
CN202210088172 2022-01-25
CN202210088172.3 2022-01-25
PCT/US2022/015711 WO2022170280A2 (en) 2021-02-08 2022-02-08 Novel anti-cd24 antibodies

Publications (2)

Publication Number Publication Date
JP2024508672A JP2024508672A (ja) 2024-02-28
JP2024508672A5 true JP2024508672A5 (enExample) 2025-02-18

Family

ID=82741874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547592A Pending JP2024508672A (ja) 2021-02-08 2022-02-08 新規抗ｃｄ２４抗体

Country Status (12)

Country Link
US (1) US20240052052A1 (enExample)
EP (1) EP4288099A4 (enExample)
JP (1) JP2024508672A (enExample)
KR (1) KR20230143177A (enExample)
CN (1) CN117412770A (enExample)
AU (1) AU2022217072A1 (enExample)
CA (1) CA3210934A1 (enExample)
CO (1) CO2023011463A2 (enExample)
IL (1) IL304898A (enExample)
MX (1) MX2023009238A (enExample)
TW (1) TW202241956A (enExample)
WO (1) WO2022170280A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4724496A1 (en) * 2023-06-09 2026-04-15 TJ Biopharma (Shanghai) Co., Ltd. Anti-cd24 antibodies and uses thereof
GB202316777D0 (en) 2023-11-01 2023-12-13 Cambridge Entpr Ltd New therapeutic use
WO2025101970A1 (en) * 2023-11-08 2025-05-15 Pheast Therapeutics, Inc. Cd24 antibodies
WO2025128830A1 (en) * 2023-12-12 2025-06-19 The Methodist Hospital Therapeutic lilrb regulation for treating neurological disorders
WO2025132836A1 (en) * 2023-12-19 2025-06-26 Pentixapharm Ag Antibodies against cd24
WO2025159754A1 (en) * 2024-01-25 2025-07-31 China Medical University Therapeutic cd24 humanized monoclonal antibodies and anti-tumor translational use
WO2025218729A1 (en) * 2024-04-17 2025-10-23 TJ Biopharma (Shanghai) Co., Ltd. Multifunctional molecules targeting cd24
CN119161485B (zh) * 2024-10-29 2026-03-24 上海中医药大学附属曙光医院 靶向GFRα3的抗体及其制备方法和在抗癌中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080002341A (ko) * 2006-06-30 2008-01-04 재단법인서울대학교산학협력재단 Ｃｄ２４를 표적으로 하는 암 억제방법
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
CN106456749B (zh) * 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
US10239950B2 (en) * 2014-04-28 2019-03-26 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
US20170158753A1 (en) * 2014-06-25 2017-06-08 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
AU2019269361C1 (en) * 2018-05-14 2025-06-12 Children's Research Institute, Children's National Medical Center Anti-CD24 compositions and uses thereof
EP3947460A4 (en) * 2019-03-26 2023-05-10 Forty Seven, Inc. MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER
WO2020261280A1 (en) * 2019-06-25 2020-12-30 Ichilov Tech Ltd. Anti-cd24 antibody and uses thereof

Similar Documents

Publication Publication Date Title
JP2024508672A5 (enExample)
JP2022545660A5 (enExample)
JP2025078629A5 (enExample)
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法
JP2024023228A5 (enExample)
RU2019126655A (ru) Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
JP2022514693A5 (enExample)
IL312224B1 (en) Guidance and navigation control proteins and method of making and using thereof
JP2020529839A5 (enExample)
EP4288099A2 (en) Novel anti-cd24 antibodies
JP2022542559A5 (enExample)
CA3079363A1 (en) Multispecific antigen binding proteins
JP2023159379A (ja) Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途
CN115066274A (zh) 三价结合分子
JP2024532482A5 (enExample)
JP2024516098A5 (enExample)
IL304295B1 (en) A bispecific antibody with a heterodimeric form with a natural antibody structure ANTI-PD-L1/ANTI-4-1BB and its preparation
JP2024504162A5 (enExample)
JP2025508317A5 (enExample)
JP2024541476A5 (enExample)
JP2024546923A5 (enExample)
JP7641292B2 (ja) 抗ｃｄ１９抗体、その使用方法及び製造方法
TW202321311A (zh) 與scFv等之連接子結合的抗體
RU2022107092A (ru) Новые анти-cldn18.2 антитела
JP2022536370A5 (enExample)